Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

1.

Adverse effects of bisphosphonates: implications for osteoporosis management.

Kennel KA, Drake MT.

Mayo Clin Proc. 2009 Jul;84(7):632-7; quiz 638. doi: 10.1016/S0025-6196(11)60752-0. Review.

PMID:
19567717
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Bisphosphonates.

McClung M.

Arq Bras Endocrinol Metabol. 2006 Aug;50(4):735-44. Review.

PMID:
17117298
[PubMed - indexed for MEDLINE]
Free Article
3.

Intravenous zoledronic acid for the treatment of osteoporosis.

Lewiecki EM.

Curr Osteoporos Rep. 2008 Mar;6(1):17-23. Review.

PMID:
18430396
[PubMed - indexed for MEDLINE]
4.

Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.

Cole RE.

Postgrad Med. 2011 Mar;123(2):131-44. doi: 10.3810/pgm.2011.03.2271. Review.

PMID:
21474901
[PubMed - indexed for MEDLINE]
5.

Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.

Hochberg MC.

Curr Osteoporos Rep. 2008 Sep;6(3):89-94. Review.

PMID:
18752769
[PubMed - indexed for MEDLINE]
6.

[Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].

Soen S.

Clin Calcium. 2011 Oct;21(10):1543-6. doi: CliCa111015431546. Review. Japanese.

PMID:
21960242
[PubMed - indexed for MEDLINE]
7.

Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?

McClung M.

Clin Obstet Gynecol. 2013 Dec;56(4):743-8. doi: 10.1097/GRF.0b013e3182a98295. Review.

PMID:
24177063
[PubMed - indexed for MEDLINE]
8.

Bisphosphonates in the treatment of osteoporosis.

Diab DL, Watts NB.

Endocrinol Metab Clin North Am. 2012 Sep;41(3):487-506. doi: 10.1016/j.ecl.2012.04.007. Epub 2012 Jun 9. Review.

PMID:
22877426
[PubMed - indexed for MEDLINE]
9.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
[PubMed - indexed for MEDLINE]
10.

Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Lewiecki EM.

Drugs. 2011 Apr 16;71(6):791-814. doi: 10.2165/11585470-000000000-00000. Review.

PMID:
21504254
[PubMed - indexed for MEDLINE]
11.

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM.

Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20. Review.

PMID:
23177553
[PubMed - indexed for MEDLINE]
12.

A review of minodronic acid hydrate for the treatment of osteoporosis.

Tanishima S, Morio Y.

Clin Interv Aging. 2013;8:185-9. doi: 10.2147/CIA.S23927. Epub 2013 Feb 15. Review.

PMID:
23440003
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Treatment of osteoporosis in women intolerant of oral bisphosphonates.

Aspray TJ, Francis RM.

Maturitas. 2012 Jan;71(1):76-8. doi: 10.1016/j.maturitas.2011.10.005. Epub 2011 Nov 10. Review.

PMID:
22079368
[PubMed - indexed for MEDLINE]
14.

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

Hamdy RC.

Drug Des Devel Ther. 2010 Nov 18;4:321-35. doi: 10.2147/DDDT.S6287. Review.

PMID:
21151620
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

[Bisphosphonate therapy for osteoporosis and bone strength].

Kishimoto H.

Clin Calcium. 2006 Sep;16(9):1513-19. Review. Japanese.

PMID:
16951477
[PubMed - indexed for MEDLINE]
16.

Safety of bisphosphonates.

Orozco C, Maalouf NM.

Rheum Dis Clin North Am. 2012 Nov;38(4):681-705. doi: 10.1016/j.rdc.2012.09.001. Review.

PMID:
23137577
[PubMed - indexed for MEDLINE]
17.

Redefining osteoporosis treatment: Who to treat and how long to treat.

Lewiecki EM, Silverman SL.

Arq Bras Endocrinol Metabol. 2006 Aug;50(4):694-704. Review.

PMID:
17117295
[PubMed - indexed for MEDLINE]
Free Article
18.

[New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].

Takeuchi Y.

Clin Calcium. 2009 Jan;19(1):85-90. doi: CliCa09018590. Review. Japanese.

PMID:
19122268
[PubMed - indexed for MEDLINE]
19.

An integrated approach: bisphosphonate management for the treatment of osteoporosis.

Owens G, Jackson R, Lewiecki EM.

Am J Manag Care. 2007 Dec;13 Suppl 11:S290-308; quiz S309-12. Review.

PMID:
18095779
[PubMed - indexed for MEDLINE]
Free Article
20.

Osteoporosis and its implications for dental patients.

Edwards BJ, Migliorati CA.

J Am Dent Assoc. 2008 May;139(5):545-52; quiz 625-6. Review.

PMID:
18451370
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk